Article Text


Viral hepatitis
PMO-181 Long term follow-up of chronic hepatitis B (HBV) patients treated with pegylated interferon: single centre experience
  1. W Smethurst,
  2. L Fenton,
  3. K Forrester,
  4. R Simpson,
  5. S Moreea
  1. Bradford Teaching Hospitals Foundation Trust, Bradford, UK


Introduction Pegylated Interferon (PEG IFN) is NICE approved for the treatment of chronic hepatitis B (HBV) but it is now known that the response is genotype dependent. To analyse the long term outcome of chronic hepatitis B patients treated with Pegylated Interferon.

Methods Retrospective analysis of our hepatitis B database to identify HBV patients treated with PEG IFN. The following data were obtained from the patient's records and our electronic reporting systems: demographics, length of treatment, ALT and viral load (HBV PCR) at various points during and after treatment.

Results 13 patients (9 males, average age 36.8 yrs; 4 females, average age 34.7 yrs) were treated from April 2007 with a mean follow-up of 33 months (133 weeks). There were 8 eAg +ve and 5 eAg –ve patients. None were co-infected with the Delta virus. In the eAg +ve group, there were 3 genotype D (South Asians), 3 genotype C (2 Chinese and 1 South Asian), 1 genotype B (South Asian) and 1 unknown genotype (white Caucasian). All had a raised ALT and mild changes (Ishak fibrosis score 0–2) on liver biopsy. 4/8 (50%)—3 Genotype C, 1 Genotype D—achieved eAg seroconversion to eAb +ve and 1/8 (13%)—unknown genotype—achieved sAg clearance at the end of treatment. ALT normalised only in those who seroconverted. HBV PCR was <200 IU/ml in 5/8 patients at week 24 and 4/8 patients had undetectable PCR at the end of treatment at week 48 (lack of data for two patients, one failed treatment and one HBV PCR 42 IU/ml). There were three cases of lamivudine resistance. Four patients relapsed within 1-year post PEG IFN (all genotype D) and required treatment with tenofovir (+/− lamivudine). In the eAg –ve group, there were four genotype D patients (all South Asians, two co-infected with HCV genotype 3a) and 1 unknown genotype (Chinese). The three non co-infected patients showed good response at the end of treatment but all relapsed within 1 year and all needed further treatment with nucleoside analogues with good viral response. The co-infected patients achieved sustained viral response for HCV and maintained a low HBV viral load.

Conclusion This study confirms good outcomes for non-genotype D patients treated with PEG IFN. However, eAg –ve patients with genotype D treated with PEG IFN tend to relapse after treatment. The use of HBsAg quantification will help to tailor treatment in the future.

Competing interests None declared.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.